Unique ID issued by UMIN | UMIN000016615 |
---|---|
Receipt number | R000019286 |
Scientific Title | Open randomized controlled trial to evaluate efficacy of clindamycin in the pulmonary Mycobacterium avium complex disease |
Date of disclosure of the study information | 2015/02/23 |
Last modified on | 2015/02/23 23:12:25 |
Open randomized controlled trial to evaluate efficacy of clindamycin in the pulmonary Mycobacterium avium complex disease
Open randomized controlled trial to evaluate efficacy of clindamycin in the pulmonary Mycobacterium avium complex disease
Open randomized controlled trial to evaluate efficacy of clindamycin in the pulmonary Mycobacterium avium complex disease
Open randomized controlled trial to evaluate efficacy of clindamycin in the pulmonary Mycobacterium avium complex disease
Japan |
Pulmonary Mycobacterium avium complex disease
Pneumology | Infectious disease |
Others
NO
To evaluate efficacy and safety of clindamycin in patients with pulmonary Mycobacterium avium complex disease in Adults
Safety,Efficacy
Findings of chest high resolution computed tomography before and after clindamycin treatment
1. Symptoms, laboratory data, spirometry
2. Bacteriological efficacy: sputum culture, and bacterial floral analysis findings of bronchoalveolar lavage fluid culture
3. Safety and adverse effects of clindamycin treatment
Parallel
Randomized
Open -no one is blinded
Active
4
Treatment
Medicine |
Oral administration of clarithromycin, rifampicin, ethambutol.
After oral administration of clarithromycin, rifampicin, ethambutol for month, add oral administration of clindamycin for two months.
Follow up.
After oral administration of clindamycin for three months, follow up.
20 | years-old | <= |
Not applicable |
Male and Female
1. Patients 20 years of age and older
2. Patients satisfying diagnostic riteria of nontuberculous mycobacteriosis and causative pathogens are Mycobacterium avium or M. intracellulare
1. Patients receiving other antibiotic treatments.
2. Contraindication for clindamycin, clarithromycin, rifampicin, ethambutol administration
3. Patients deemed ineligible by the attending physicians for various reasons.
4. Patients with serious heart disorders
100
1st name | |
Middle name | |
Last name | Kei Yamasaki |
University of Occupational and Environmental Health, Japan
Department of Respiratory Medicine
1-1, Iseigaoka, Yahata-nishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan
093-603-1611
kkyamsaki1019@yahoo.co.jp
1st name | |
Middle name | |
Last name | Kei Yamasaki |
University of Occupational and Environmental Health, Japan
Department of Respiratory Medicine
1-1, Iseigaoka, Yahata-nishi-ku, Kitakyushu, Fukuoka, 807-8555, Japan
093-603-1611
kkyamsaki1019@yahoo.co.jp
Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan
Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan
Self funding
NO
2015 | Year | 02 | Month | 23 | Day |
Unpublished
Enrolling by invitation
2015 | Year | 02 | Month | 09 | Day |
2015 | Year | 02 | Month | 24 | Day |
2015 | Year | 02 | Month | 23 | Day |
2015 | Year | 02 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019286